

STUDY PROTOCOL

Open Access



Adolescent Coordinated Transition (ACT) to improve health outcomes among young people living with HIV in Nigeria: study protocol for a randomized controlled trial

Nadia A. Sam-Agudu^{1,2}, Jennifer R. Pharr³, Tamara Bruno³, Chad L. Cross⁴, Llewellyn J. Cornelius⁵, Prosper Okonkwo⁶, Bolanle Oyeledun⁷, Hadiza Khamofu⁸, Ayodotun Olutola⁹, Salome Erekhaha¹, William Nii Ayitey Menson³ and Echezona E. Ezeanolue^{3*}

Abstract

Background: Adolescents living with HIV (ALHIV) have worse health outcomes than other populations of people living with HIV. Contributing factors include lack of standard and comprehensive procedures for ALHIV transitioning from pediatric to adult care. This has contributed to poor retention at, and following transition, which is problematic especially in high ALHIV-burden, resource-limited settings like Nigeria.

Methods: Using a two-arm cluster randomized control design, the Adolescent Coordinated Transition (ACT) trial will measure the comparative effectiveness of a graduated transition and organized support group intervention against the usual practice of abrupt transfer of Nigerian ALHIV from pediatric to adult care. This study will be conducted at 12 secondary and tertiary healthcare facilities (six intervention, six control) across all six of Nigeria's geopolitical zones. The study population is 13- to 17-year-old ALHIV ($N = 216$, $n = 108$ per study arm) on antiretroviral therapy. Study participants will be followed through a 12-month pre-transfer/transition period and for an additional 24 months post transfer/transition. The primary outcome measure is the proportion of ALHIV retained in care at 12 and 24 months post transfer. Secondary outcome measures are proportions of ALHIV achieving viral suppression and demonstrating increased psychosocial wellbeing and self-efficacy measured by psychometric tests including health locus of control, functional social support, perceived mental health, and sexual risk and behavior.

Discussion: We hypothesize that the ACT intervention will significantly increase psychosocial wellbeing, retention in care and ultimately viral suppression among ALHIV. ACT's findings have the potential to facilitate the development of standard guidelines for transitioning ALHIV and improving health outcomes in this population. The engagement of a consortium of local implementing partners under the Nigeria Implementation Science Alliance allows for nationwide study implementation and expedient results dissemination to program managers and policy-makers. Ultimately, ACT may also provide evidence to inform transitioning guidelines not only for ALHIV but for adolescents living with other chronic diseases in resource-limited settings.

Trial registration: ClinicalTrials.gov, ID: NCT03152006. Registered on May 12, 2017.

Keywords: HIV, Healthcare transition, Adolescent, Retention, Viral suppression, Mental health, Nigeria

* Correspondence: ezeanolue@gmail.com; echezona.ezeanolue@gmail.com

³Global Health Initiative, School of Community Health Sciences, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, USA
Full list of author information is available at the end of the article

Background

Between 2005 and 2012, global acquired immunodeficiency syndrome (AIDS)-related deaths fell by 30% among people living with human immunodeficiency virus (HIV); however, mortality among adolescents living with HIV (ALHIV) increased by 50% in the same period [1]. Nearly 92% of these deaths occurred in sub-Saharan Africa, where AIDS is the leading cause of mortality among adolescents [2–4]. Of the estimated 1.75 million ALHIV in sub-Saharan Africa, approximately 240,000 are living in Nigeria, which represents the second highest burden of adolescent HIV globally [2]. In 2013, an estimated 11,000 deaths occurred among Nigerian ALHIV, representing 9.2% of AIDS-related deaths among all African adolescents [2].

Loss to follow-up (LTFU) and poor retention in care are associated with increased risk of mortality and morbidity among ALHIV [5, 6]. Studies have demonstrated that LTFU rates are higher and retention lower among ALHIV, compared to adult patients [6, 7]. A recent nationwide study reported a LTFU rate among Nigerian ALHIV at 16.1% after a mean follow-up of 28 months [8]. In addition to LTFU, poor adherence to antiretroviral therapy (ART) results in virologic treatment failure and contributes to increased mortality among adolescents [9–11].

The healthcare transition period is particularly high risk for LTFU and other poor health outcomes among ALHIV. Healthcare transition is defined as “the purposeful, planned movement of adolescents and young adults with chronic physical and medical conditions from child-centered to adult-oriented healthcare systems” [12]. Barriers to successful transition have been categorized as: (1) patient/family related (e.g., knowledge deficits in self-management skills); (2) provider-related (e.g., lack of time for transitioning, confusion about roles, and pediatricians’ belief that adult providers would provide inadequate care); and (3) system-related (e.g., lack of formal transitioning program, lack of trained adult providers to competently care for transferred adolescents, and challenges in establishing an interdisciplinary team) [13].

A recent nationwide survey conducted by our study group determined that Nigerian ALHIV are routinely transferred from pediatric to adult care at age 15 or 18 years [14]. Factors limiting successful transition and post-transition retention include: lack of preparation, poor logistics, poor communication between pediatric and adult providers, loss of the “pediatric family” relationships of ALHIV, transition readiness and system-related issues such as access to care, and continuity of care post transition [15].

The most commonly identified components of successful transition include: provision of psychological support to help adolescents deal with anxieties and anger, provision of information, e.g., on risky sexual behavior and access to/navigation of medical services, and providing education on

disease state and the importance of adherence to treatment [16–21]. Nigerian ALHIV are also reported to seek social support as a coping strategy for stress related to visiting the hospital and taking drugs regularly [22]. Additional factors that promote successful healthcare transition for ALHIV include: open communication between pediatric and adult staff, peer educator support, access to tailored HIV information, and capacity-building for ALHIV to meet their own psychosocial needs especially in self-efficacy and self-esteem [4, 16–20].


While national policy documents in Nigeria recognize HIV among adolescents as an important issue, none of them address healthcare transition and no guidelines exist for transition of Nigerian adolescents living with HIV or, for that matter, any chronic health condition [23, 24]. Therefore, there is an urgent need to develop a feasible, acceptable, and sustainable model of healthcare transitioning for adolescents in Nigeria. Nigeria’s healthcare system remains weak, and HIV care is predominantly foreign donor-supported [25]. Any new intervention or program should require relatively little additional external funding. Thus, the intervention we propose, Adolescent Coordinated Transition (ACT), is designed to integrate well with, and exert leverage on, the existing healthcare system whilst incorporating effective strategies for healthcare transition.

Conceptual framework

The ACT intervention relies on the social cognitive theory (SCT) (Fig. 1). Although we considered other frameworks such as the Health Belief Model and the Ecological Model, the constructs of the SCT are particularly relevant to HIV/AIDS treatment and risk reduction among adolescents. Many identified challenges lie with the adolescent or within their environment. SCT recognizes that health behavior is influenced by factors within the person (knowledge of the importance of HIV treatment, how to access treatment during transition, and self-efficacy for service utilization in adult clinics) as well as facilitators or barriers within a person’s social and structural environment (the HIV clinic, peers, or support groups).

Study objectives and hypotheses

This study’s primary objective is to measure the comparative effectiveness of the ACT intervention versus usual care on post-transfer retention in care among ALHIV at 12 and 24 months post transfer. The ACT intervention encompasses a graduated transition period coordinated with an organized support group, which aims to increase retention rates among ALHIV after transfer to adult care. The coordination denotes a complementary pediatric-adult team approach to support the



clinical and psychosocial health of the transitioning ALHIV. The graduated transition provides an extended period of time for the transitioning ALHIV to become familiar with adult care while separating from pediatric care. A transition period, rather than abrupt transfer, minimizes the grief associated with the loss of the pediatric “family” and maximizes opportunities for the ALHIV and adult care providers to establish trusting relationships. The ACT intervention is to be compared to the usual care which is abrupt transfer of ALHIV to adult care with neither a transition period nor an organized support group.

ACT’s secondary objectives are:

- To measure the comparative effectiveness of the ACT intervention versus usual care on post-transfer viral suppression rates among ALHIV at 12 and 24 months post transfer
- To measure the comparative effectiveness of the ACT intervention versus usual care on psychosocial wellbeing as measured by psychometric tests at 12 and 24 months post transfer

We hypothesize that:

1. Compared to those exposed to usual care, ALHIV exposed to the ACT intervention will have significantly higher rates of retention in care
2. Compared to those exposed to usual care, ALHIV exposed to the ACT intervention will have significantly higher rates of viral suppression and higher scores on psychometric testing indicating better psychosocial wellbeing

Formative consultations

Key information that shaped the design of this study came from multiple formative consultations across the Nigeria Implementation Science Alliance (NISA), a collaboration of the 20 largest HIV implementing partners in Nigeria supported by the President’s Emergency Plan

for AIDS Relief (PEPFAR) [26]. NISA-wide consultations held with experienced Nigerian healthcare providers highlighted lack of a transition process for adolescents with common chronic illnesses in Nigeria. There are no guidelines or standard practices for healthcare transitioning for sickle cell anemia, diabetes, asthma, or HIV in Nigeria. As such, the standard of care either is absent or varies widely between providers, healthcare facilities and different parts of the country.

During recent assessments for the establishment of PEPFAR-supported adolescent HIV clinics across NISA’s network, we consulted with Nigerian ALHIV. We found ALHIV eager to be involved in their own healthcare including transitioning; however, they uniformly expressed feeling more comfortable in pediatric care because of time and attention rendered to them. Lessons learned from these consultations (e.g., the need for adult care providers to establish trust with ALHIV, a transition period and not abrupt transfer, and adolescent-friendly psychosocial support) provided critical contextual data to inform our intervention.

Methods

Study design

The study is a two-arm, cluster-randomized controlled trial that compares the effectiveness of a graduated, coordinated healthcare transition plus organized support group intervention with the usual care of abrupt transfer among ALHIV. ACT adopts the Type 1 Hybrid Design described by Curran and colleagues, which tests the effect of an intervention on relevant outcomes while observing and gathering information on the implementation of the intervention [27]. The Type 1 Hybrid Design integrates impact and process evaluation with the dual goal of testing intervention effectiveness while identifying factors influencing implementation in context. ACT’s intervention effectiveness will be addressed through measurement and analyses of the primary and secondary objectives. Intervention implementation will be measurement utilizing the RE-AIM framework as a guide for implementation indicators (described in detail below) [28].

Study setting

The ACT trial is a nationwide study that will be conducted across all six geopolitical zones of Nigeria, namely, the north-west, north-east, north-central, south-west, south-south and south-east zones. Two study sites were selected from each zone to ensure that the intervention is generalizable across the country and can be scaled up expediently if proven effective. The ACT trial is to be implemented by five PEPFAR implementing partners who are NISA members: APIN Public Health Initiatives Limited (APIN), the Center for Clinical Care and Clinical Research Nigeria (CCCRN), Centre for Integrated Health Programs (CIHP), FHI 360 Nigeria, and the Institute of Human Virology Nigeria (IHVN). Collectively, these five organizations support more than 850 comprehensive HIV treatment clinics in multiple settings across Nigeria and provide HIV services to over 24,000 ALHIV of 10 to 19 years old.

Site selection and randomization

Study sites were selected from among secondary- and tertiary-level PEPFAR-supported healthcare facilities with at least 12 months’ experience in providing comprehensive HIV care and treatment services. Eligible sites were further expected to meet the following criteria:


- At least 20 ALHIV enrolled in care as of 31 July 2016
- Separate pediatric and adult HIV care teams and clinics
- At least one dedicated physician and one dedicated nurse for each pediatric and adult HIV clinic

All sites were assessed using a standardized tool to determine whether they met the selection criteria.

Our desire was to meet the suggestions of the Consolidated Standards of Reporting Trials (CONSORT) “extension for cluster designs” checklist in our randomization procedure. To that end, we provide details here of both sequence generation and allocation [29]. Twelve healthcare facilities were selected and randomized 1:1 to the intervention and control arms (Fig. 2). These 12 study sites were pair-matched by geographic location and level of care and then randomly assigned to the intervention group (IG) or to the control group (CG). Particular attention was paid to remove bias of group assignment by concealment at the individual participant level. The randomization of facilities was carried out using scripting language in R (v. 3.3.2) by the project statistician [30]. We first created a random number between 1000 and 10,000 and used the result to seed the group assignment so that the results would be reproducible. Based on the pair-matched locations and level of care, we used the “sample” function to determine which member of each matched facility pair would be assigned to each of CG and IG. Of note, age at transfer for each study site was considered in order to include sites that transferred at 15 years as well as 18 years, according to the results of our survey [14]. All enrolled study participants receiving care at each study site will follow the procedures of their respective randomization arms described below.

Study population

Study participants will be selected from among ALHIV enrolled in care at participating healthcare facilities.



Inclusion and exclusion criteria

Inclusion criteria

1. Documented HIV infection
2. Enrolled in HIV care and taking ART at a designated ACT study site
3. Age 13–17 years: this allows for the following: alignment with target ages for routine transfer for healthcare facilities in Nigeria of 15- and 18-year-olds [14]; the pre-transfer 12-month transition period plus organized support group in the IG while CG is simply observed; and flexibility (albeit limited) in recruitment and study transfer age given the observed flexibility in age at transfer in actual practice
4. Aware of HIV diagnosis

Exclusion criteria

1. Unable or unwilling to provide assent/consent
2. Not medically stable

Description of the ACT intervention

The ACT intervention is adapted and modified from the model described by Mauro et al. as shown in Fig. 3 [19]. The model is adapted to national guideline-recommended schedule of clinic visits every 3 months [31]. ACT has three main components:

1. Alternating pediatric-adult visits during the 12-month transition period that allows both adult and pediatric clinicians and the transitioning adolescent to address difficulties related to transition and adapt to the termination of the pediatric provider-patient relationship. Transition period clinic visits will be staggered as a Pediatric-Adult-Pediatric-Adult (PAPA) model with a target of four visits in total
2. A monthly peer-led organized support group (OSG) facilitated by trained young adults living with HIV and guided by a standardized six-module curriculum covering HIV Basics, Treatment and adherence, Support networks, Adolescent rights, Living positively, and Member choice. The OSG curriculum will address topics that will enhance the adolescent’s knowledge of HIV disease and how to self-manage their medical care. Overall, the OSG targets factors that may impact the patient’s transition readiness and psychosocial health measures. ALHIV will have the opportunity to contribute to curriculum content as their OSGs evolve and mature. The OSG will be initiated at enrollment and continued through the 12-month transition period, but to assess potential impact after transfer, it will be extended to the end of the follow-up period at 24 months post transfer
3. A case management team consisting of a physician, a nurse, and a trained patient advocate. Patient




Fig. 3 Adolescent Coordinated Transition (ACT) transitioning model showing the 12-month pre-transfer period (adapted from Mauro et al. [19])

advocates already exist in these clinics and are usually HIV-infected adults who are selected based on exemplary treatment adherence and clinic attendance. The patient advocate will accompany study participants to all four PAPA clinic visits and will support the peer facilitator to lead the OSG

In the intervention arm, ALHIV will be transitioned from pediatric to adult care over a period of 1 year. Participants will be enrolled when they are approximately 1 year younger than the routine age of transfer at each study facility (either 15 or 18 years of age). During the 12-month pre-transfer period, ALHIV will be scheduled for clinic visits per the PAPA model. Patient advocates will accompany adolescents to each PAPA clinic visit. In addition, ALHIV receiving care at intervention sites will be encouraged to attend monthly OSG meetings. OSG meetings will be scheduled with routine clinic visits and at adolescent-friendly times to minimize logistical problems and to increase attendance and sustainability. Each OSG will include up to 25 participants.

Description of the control condition/usual care

The usual “transition” of care for ALHIV in Nigeria is abrupt transfer to adult care. For this protocol, “transfer” is defined as immediate handover of the ALHIV from pediatric to adult care, without a transition period, and no formal or documented communication between pediatric and adult providers prior to, or after transfer. There is also no structured pre-transfer education and/or counseling provided to ALHIV and their caregivers

with respect to procedures and expectations in adult care. In CG clinics, ALHIV will stop accessing pediatric care and start accessing the adult HIV clinic at the routine age of transfer at the facility. Adolescents will have access to all available services at the adult clinic including any adult support groups that may be available.

Participant recruitment

The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure includes the timeline for study enrollment, intervention, and assessment (Fig. 4). Study participants will be recruited and enrolled onsite at the 12 study sites. Staff of the five participating local organizations will work with study site staff to identify eligible participants. The site staff will create a master list of eligible ALHIV aged between 13 and 17 years who are enrolled in HIV care at their specific site. Parents and guardians of eligible participants will be briefly informed about the study, and after indicating interest, will be approached by trained ACT research assistants for written informed consent at routine clinic visits during the recruitment period. Research assistants will thoroughly explain all study procedures and obtain consent. Assent will be obtained from eligible 13- to 17-year-old ALHIV wards of consenting parents/guardians. Written informed consent will be obtained from eligible ALHIV under 18 years old who are deemed mature or emancipated minors and meet the following criteria: have been granted the status of adulthood by a court order; have lived independent of parental guidance for a minimum of 1 year; are married; are living on the

TIMEPOINT	Study Timeline					
	Enrollment	Pre-transfer	Transfer	Post-transfer		Follow-up
	Month 0	Month 1-12	Month 12	Month 18	Month 24	Month 36
ENROLMENT:						
Eligibility screen	X					
Informed consent	X					
INTERVENTIONS:						
PAPA Clinic Visits		X				
Organized Support Groups		←————→				
Enhanced Case Management		←————→				
ASSESSMENTS:						
Viral Load	X		X	X	X	X
Readiness assessment	X		X			
Psychological Wellbeing	X		X		X	X
Retention assessment					X	X

Fig. 4 Schedule of enrollment, interventions, and assessments

streets; or are the head of their household [32]. It is expected that recruitment will be completed between 1 July and 1 December 2017 (Additional file 1).

Data collection

After obtaining informed consent and/or assent, research assistants will collect sociodemographic and medical history information onto enrollment forms by face-to-face interview with study participants and/or their caregivers. Four psychosocial health questionnaires (described below) will also be completed at enrollment by study participants. Completion of the four questionnaires will be repeated at 12, 18, 24, and 36 months after enrollment, coinciding with the transfer time point, and 6, 12, and 24 months post transfer, respectively (Table 1). Blood viral-load sampling will be performed on the same schedule, and the results of all viral-load tests will be reported to clinic providers and filed in participants' medical charts for use in HIV management. Per national treatment guidelines, stable patients who have been on HIV treatment for at least 6 months should have at least one viral-load test every year [31]. Clinic visits will also be tracked to measure the primary outcome of retention in care.

In addition to collection towards evaluating the intervention's effectiveness on primary and secondary outcomes, we will also collect data to describe and assess the implementation process, using the RE-AIM framework [28]. This will include: (1) Reach – the number and proportion of ALHIV willing to participate in ACT; (2) Adoption – the number and proportion of partner sites willing to implement the study; (3) Implementation – fidelity to the study protocol, including consistency of delivery of the alternating pediatric and adult clinic visits (PAPA); formation, curriculum adherence, and attendance at OSGs; presence and functionality of case management teams; and (4) Maintenance – the extent to which ACT becomes institutionalized at the intervention sites after completion of study follow-up [28].

Outcome measures

The primary outcome measure is the *proportion of ALHIV retained in care at 12 and 24 months post transfer*. For this study, retention is defined as having made at least two clinic visits separated by a 6-month period within 12 months and at least four visits each separated by at least 6 months within 24 months post transfer. Hence, there are two primary outcome measures, with the long-term (24-month) retention measurement being a necessary “composite” of those who would have already demonstrated short-term (12-month) retention.

Secondary outcome measures are as follows:

1. *Proportion of ALHIV achieving viral suppression measured at 12 and 24 months post transfer*. Viral

suppression is defined per the 2016 Nigerian national HIV guidelines as < 20 copies of HIV ribonucleic acid (RNA) per milliliter of blood plasma after at least 6 months of taking ART [33]

2. *Proportion of ALHIV demonstrating psychosocial wellbeing during study follow-up*. This study team has previously reported that poor psychosocial wellbeing and lack of adequate coping/self-efficacy skills are potential barriers to successful outcomes, including transitioning for this population in Nigeria [22, 34]. In order to generate more comprehensive evidence on wellbeing and resilience among ALHIV, we will administer four questionnaires among our study cohort: (1) the Health Locus of Control (HLC) scale will assess the extent to which ALHIV consider their health and health decisions to be within, or outside of their control; (2) the Mental Health Continuum-Short Form (MHC-SF) will measure the constructs of social, emotional, and psychological wellbeing; (3) the Functional Social Support Questionnaire (FSSQ) will evaluate the strength of the social support network of ALHIV; and (4) the psychosocial determinants of sexual risk behavior using the Sexual Risk Behavior, Beliefs, and Self-efficacy (SRBBS) scale will investigate for key psychosocial variables affecting ALHIV sexual risk-taking or protective behaviors [34–40]

The HLC tool has previously been validated by our research team among Nigerian ALHIV, and the MHC-SF has been validated among South African adolescents and adults [34, 40]. All the aforementioned tools will be administered by trained research assistants to study participants for a total of five times during the 3-year follow-up: at enrollment, transfer, and at 6, 12, and 24 months post transfer (Table 1). Additionally, healthcare transition readiness will be assessed twice (at enrollment and at transfer) using the Transition Readiness Assessment Questionnaire (TRAQ) [41, 42]. In a recent systematic review, the TRAQ was determined to be the best-validated transition tool with robust content and construct validity, as well as internal consistency [43].

Sample size estimation

The design requires two arms (control = direct transfer without transition period or OSG and intervention = graduated transition with OSG). Six geopolitical zones are included in the design, with two sites (one replicate per arm) located in each zone. The factors considered for the sample size estimate are: at least 80% power, assuming 20% effect size, a confidence level of 95%, a correlation among repeated measures of 0.3, and an intra-class correlation within clusters of 0.05. Further, we assume equal numbers

Table 1 Adolescent Coordinated Transition (ACT) study timeline, visits, and procedures

Visit	Timeline	Study visit	Procedure	Intervention group	Control group
Enrollment	0 months	Yes	Enrollment	Yes	Yes
			Readiness assessment	Yes	Yes
			Psychosocial assessment ^a	Yes	Yes
			Viral load	Yes	Yes
Visit 1	3 months	Yes	Type of clinic	Pediatric clinic	Pediatric clinic
			Organized support group	Yes	No
			Readiness assessment	Yes	Yes
Visit 2	6 months	Yes	Type of clinic	Adult clinic	Pediatric clinic
			Organized support group	Yes	No
			Readiness assessment	Yes	Yes
Visit 3	9 months	Yes	Type of clinic	Pediatric clinic	Pediatric clinic
			Organized support group	Yes	No
			Readiness assessment	Yes	Yes
Visit 4	12 months	Yes	Type of clinic	Adult clinic	Pediatric clinic
			Organized support group	Yes	No
			Readiness assessment	Yes	Yes
			Viral load	Yes	Yes
Transfer to adult care					
Visit 5	15 months	No	Type of clinic	Adult clinic	Adult clinic
			Organized support group	Yes	No
Visit 6	18 months	Yes	Type of clinic	Adult clinic	Adult clinic
			Organized support group	Yes	No
			Viral load	Yes	Yes
Visit 7	21 months	No	Type of clinic	Adult clinic	Adult clinic
			Organized support group	Yes	No
Visit 8	24 months	Yes	Readiness assessment	Yes	Yes
			Psychosocial Assessment ^a	Yes	Yes
			Viral load	Yes	Yes
End Visit	36 months	Yes	Type of clinic	Adult clinic	Adult clinic
			Readiness assessment	Yes	Yes
			Psychosocial Assessment ^a	Yes	Yes
			Viral load	Yes	Yes

^aPsychosocial assessments performed with Health Locus of Control, Mental Health Continuum-Short Form, Functional Social Support Questionnaire and Sexual Risk Behavior, Beliefs, and Self-efficacy tools

of clusters between CG and IG, and clusters within those conditions to be of equal size. Based on these assumptions, a baseline number of 15 participants per site was needed. This was, however, adjusted for several assumed losses. Based on knowledge of healthcare in this area and among target participants, the following participant loss estimates were made: healthcare transfers out of study sites at 5%, participant moving out of study area at 5%, deaths during the study at 7%, and study withdrawal/dropout at 5%. This results in a total of 22% dropouts, requiring an additional three participants (15×0.22) for a total of 18 participants

per site. Additionally, we anticipate a 30% rate for declining to participate. Hence, we will need to approach an additional five ALHIV (18×0.3) for a total of 23 ALHIV currently enrolled as taking ART at study initiation to ensure that the requirement of 18 participants per site is met. Therefore, for two arms across six zones, we have a recruitment goal of 276 ALHIV ($23 \times 2 \times 6$) with a desired final sample size of 216 ALHIV ($18 \times 2 \times 6$) consented to participate. Sample size estimation was performed using G*Power (v. 3.1.9.1, Universität Düsseldorf, Germany) and Sampsize (v 0.6, P. Glaziou, ampsize.sourceforge.net) with appropriate adjustments for cluster randomization [44].

Statistical analysis

For the primary objective, the study will assess the differential impact that the ACT intervention has on the primary outcome of retention. For this measure, ACT will test the difference in the percentage of study participants completing scheduled clinic visits under the hypothesis that the IG's percentages will exceed CG percentages from baseline to 12 months ("short-term" retention) and to 24 months ("long-term" retention) following transfer to adult care. An initial test of proportions will be conducted at each time period to compare these percentages using a one-way test, and exact p values will be calculated using a permutation distribution. Additionally, a Poisson regression model with a time offset will be explored, which will allow for the development of a model to compare rates between the control and intervention arms while accounting for events (i.e., retention) per unit time, which allows time to vary for each subject as well as allowing the inclusion of potential covariates (for example, age, and time since HIV diagnosis).

Similarly, for secondary objective 1, the study will assess the differential impact that the intervention has on viral suppression. For this measure, ACT will test the difference in the percentage of study participants achieving viral suppression, under the hypothesis that the IG percentages will exceed CG percentages at each time period. The strategy in this analysis is similar to that of the primary objective: a one-way test of proportions will be conducted initially, followed by a Poisson count model to account for potential covariates of interest in addition to a temporal component.

For secondary objective 2, the study will assess whether the ACT intervention leads to improvements in the social, emotional, and psychological wellbeing of study participants; improvements in their self-efficacy; or changes in their health locus of control (HLC) from an external to an internal locus of control. Additionally, ACT aims to understanding the potential of psychologically based intervening variables to influence important study outcomes (i.e., increased retention rates and suppressed viral load). To examine important temporal changes in psychological factors, mean changes will be calculated for HLC, FSSQ, MHC-SE, and SRBBS scores from the transfer baseline to 12 and 24 months post transfer. Additionally, between-group comparisons will be made using repeated-measures analysis of variance (ANOVA). Owing to multiple tests among the same subjects, an approximate type 1 error of .05 will be maintained either directly through the use of a technique designed to accommodate repeated-measures designs (e.g., RM-ANOVA), or through the use of post-hoc adjustment of p values (e.g., Bonferroni's method).

Simultaneously, ACT will examine direct and indirect contribution of psychosocial factors on viral-load suppression and retention of study participants in both

study arms through multiple mediation model analyses as recommended by Preacher and Hayes [45]. Mediation analyses are particularly useful in randomized control trials as they attempt to capture the effects or processes that occur after randomization. As noted by Preacher and Hayes, the multiple mediation model is preferred over the traditional simple mediation model [45]. Additional mediator/moderator models will also be explored in order to investigate the potential direct and indirect impacts of other ACT intervention components; these will include the use of peer-led support groups during the pre- and post-transfer period, and the relative impact of case management support on retention rates and viral-load measures.

Data management

Personal health information (PHI) and all study data will be kept confidential following the Health Insurance Portability and Accountability Act (HIPAA) and Nigeria's National Health Research Ethics Committee guidelines. We will implement strategies at each stage to reduce the potential for breach in confidentiality and inadvertent disclosure of PHI. Collected information in paper form will be stored in a locked, fireproof cabinet in the Nigeria-based principal investigator's (PI's) office. Data will be abstracted and stored in an electronic database which will be encrypted and accessed by PIs, study coordinators and data management staff only. De-identified data will be made available to other members of the team, such as the biostatistician, on a need-to-know basis. Blood samples for viral load will be collected according to established protocol at each study site, and analyzed onsite or at an established referral laboratory with a de-identified code. The results will be available directly to the research team from the laboratory, and also filed in the clinic chart for access by medical providers.

Data Monitoring Committee

The Data and Safety Monitoring Board (DSMB) will comprise four professionals in the research or HIV/adolescent care field and one layperson; a patient advocate from the study community.

The DSMB will perform the following functions:

- Review the research protocol and data and safety monitoring procedures, and evaluate the progress of the interventional trial
- Recommend halting the trial if it perceives that harm is occurring due to the intervention
- Meet with PIs at least once annually to review adverse event reports, participants' complaints if any, and accrual

- Evaluate confidentiality and integrity of the database, and the procedure for storing confidential files
- Make recommendations to the study funder, relevant ethics committees, and investigators concerning continuation or conclusion of the trial

Study staff recruitment and training

In the intervention arm, each participating healthcare facility will identify a staff member (nurse/midwife/social worker/expert patient) who will serve as the patient advocate on the site's case management team. Along with the pediatric and adult HIV clinic focal persons, the patient advocate will form a case management team to coordinate care and support the ALHIV through the graduated transition. Peer facilitators may be selected by the healthcare team or nominated by ALHIV clients at the site, where appropriate. Central study coordinators and implementing partner-specific study coordinators from each of the five local ACT organizations have also been identified.

Training will be conducted in three phases:

1. A central training to orient focal persons, study coordinators, data manager, and support group staff to the study and to obtain feedback on study instruments
2. A second central training will be held to train research assistants on study protocols, ethical considerations, and data collection and management
3. Site-level trainings will be conducted for research assistants, peer facilitators, and other site-level research staff. Training will focus on study procedures including recruitment and enrollment, ethics, and OSG establishment and facilitation. Peer facilitator training will be based on four existing guides for organizing HIV support groups: "Positive Connections" [46], the INSPIRE MoMent Nigeria curriculum [47], Africaid's Zvandiri curriculum [48], and the Malawi Teen Club Curriculum [49]

Discussion

Nigeria is a country with a high HIV burden, with the second largest population of ALHIV worldwide. Therefore, successful interventions in Nigeria will have significant impact on health outcomes indicators among ALHIV in Africa and globally. Ineffective transfer from pediatric to adult care is associated with poor health outcomes. This can be addressed with comprehensive transition procedures that attend to the adolescent's psychosocial needs, reducing the sense of loss at leaving the pediatric family, establishing trust in the adult care team, and providing peer support. Ultimately, higher post-transition retention in care, treatment adherence,

and psychosocial wellbeing can be achieved for this population.

Strengths

The ACT trial has several strengths. The study team's Nigeria and U.S.-based researchers have extensive HIV research and program experience, a well-established local presence, and a track record of successfully conducting implementation research in Nigeria. The design is a cluster-randomized trial built on existing programs, which allows for determination of the real-life effectiveness of the intervention using triangulation of multiple concurrent data collection methods. Additionally, the ACT trial's intervention encompasses the core elements of healthcare transitioning, including a standard transition procedure, transition readiness assessment, tracking, monitoring, and planning, and transfer of care. Lastly, the trial has strong support from local implementing partners that exert leverage on existing in-country PEPFAR investments, familiarity with local communities and the support of collaborating sites and government agencies.

Potential limitations

There are some potential limitations in our study. First, HIV care at the 12 study sites is supported by five different NGOs, which might create some difficulties for coordination and quality control of study activities. To mitigate this potential problem, one NGO, IHVN, is charged with centrally coordinating and maintaining quality control for key study activities and data. Related to this, to ensure an acceptable level of quality of care for ALHIV, we also restricted eligibility to facilities with experience in and adequate staffing for HIV care delivery. However, this might reduce the generalizability of our findings for facilities with limited staffing. Lastly, our study population comprises adolescents who are likely mostly perinatally infected, which may limit the applicability of study findings among adolescents who acquired HIV through other routes of transmission.

Potential implications for practice and research

Findings from the ACT trial will potentially contribute evidence towards addressing the high AIDS-related mortality rates observed among adolescents, especially in sub-Saharan Africa. Implementation research that utilizes the large PEPFAR and other funding investments and existing program infrastructure in resource-limited countries is more likely to be feasible, sustainable and expediently scalable. Finally, successful transition models for adolescents living with HIV can be adopted into research and/or practice for adolescents living with other chronic illnesses such as sickle cell anemia, asthma, and diabetes. Findings from this trial will be communicated through scientific publications, international and local

conference presentations, and dissemination to policy-makers.

Future research

Given the importance of cost-effectiveness in the selection and design of the study interventions, cost-effectiveness analysis for the ACT intervention is planned, especially where findings show significant positive impact on study outcomes.

Trial status

Recruitment of participants for this study started the week of 26 June, 2017 and is expected to end on 1 December 2017. This trial was registered with ClinicalTrials.gov (NCT03152006) on 16 May 2017.

Additional file

Additional file 1: SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 118 kb)

Abbreviations

ACT: Adolescent Coordinated Transition; ALHIV: Adolescents living with HIV; APIN: APIN Public Health Initiatives Limited; ART: Antiretroviral therapy; CCCRN: Center for Clinical Care and Clinical Research; CIHP: Center for Integrated Health Programs; DSMB: Data Safety Monitoring Board; FSSQ: Functional Social Support Questionnaire; HIPAA: Health Insurance Portability and Accountability Act; HLC: Health Locus of Control; IHVN: Institute of Human Virology; LTFU: Loss to follow-up; MHC-SF: Mental Health Continuum-Short Form; NHREC: National Health Research Ethics Committee; NISA: Nigeria Implementation Science Alliance; OSG: Organized support group; PAPA: Pediatric-Adult-Pediatric-Adult; PEPFAR: President's Emergency Plan for AIDS Relief; PHI: Personal health information; SCT: Social cognitive theory; TRAQ: Transition Readiness Assessment Questionnaire

Acknowledgements

The ACT team thanks the Nigerian Federal Ministry of Health and the Nigeria Implementation Science Alliance for their enabling support of the study. The authors gratefully acknowledge the study coordinators and staff from APIN, CCCRN, CIHP, FHI 360, and IHVN for their valuable contributions to study design and site assessments and selection. The SPIRIT Checklist [50] was used to ensure that recommended items were addressed in this protocol.

Funding

The ACT trial is supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under award number R01HD089871 to EEE and NASA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding agencies played no role in the study conception or design and will not play a role in data collection, data analysis, data interpretation, or writing of the report.

Availability of data and materials

Not applicable

Authors' contributions

NASA conceived the study and the design, contributed to data collection and manuscript draft, and approved the final draft. JP contributed to the study design, drafting of the manuscript, and approved the final draft. TB, SE, and WNM contributed to the design and data collection, critically reviewed the manuscript for intellectual content, and approved the final draft. CLC contributed to the design and statistical estimations, critically reviewed the manuscript for intellectual content and approved the final draft. LJC contributed to the design, critically reviewed the manuscript for intellectual content and approved the final draft. Implementing partner co-investigators

(PO, BO, HK, and AO) critically reviewed the manuscript for intellectual content and approved the final draft. EEE conceived the study and the design, contributed to data collection and manuscript draft, and approved the final draft. All authors read and approved the final manuscript.

Ethics approvals and consent to participate

The ACT trial has been approved by the Institutional Review Boards (IRBs) of the University of Nevada Las Vegas (#990070-4) and the University of Maryland (#HP-00075335), as well as the Nigerian National Health Research Ethics Committee (NHREC/01/01/2007-25/04/2017). Written informed consent will be obtained from parents/guardians and eligible emancipated minor ALHIV, and assent will be obtained from all eligible minor ALHIV. All IRBs will be notified of any modifications to the protocol.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Pediatric and Adolescent HIV Unit, Clinical Services, and International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria. ²Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, OH, USA. ³Global Health Initiative, School of Community Health Sciences, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, USA. ⁴School of Medicine and School of Community Health Sciences, University of Nevada, Las Vegas, NV, USA. ⁵School of Social Work and College of Public Health, University of Georgia Athens, Athens, GA, USA. ⁶APIN Public Health Initiatives, Abuja, Nigeria. ⁷Centre for Integrated Health Programs, Abuja, Nigeria. ⁸FHI 360, Abuja, Nigeria. ⁹Center for Clinical Care and Clinical Research Nigeria, Abuja, Nigeria.

Received: 22 June 2017 Accepted: 23 November 2017

Published online: 14 December 2017

References

- UNAIDS. Report on the Global AIDS Epidemic 2013. 2013. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf. 2016.
- UNAIDS, "HIV indicators," AIDSinfo 2016 Data, 2017. [Online]. Available at: <http://aidsinfo.unaids.org/>.
- World Health Organization. Health for the world's adolescents: a second chance in the second decade. 2014 Available at: http://apps.who.int/iris/bitstream/10665/112750/1/WHO_FWC_MCA_14.05_eng.pdf?ua=1. 2015.
- World Health Organization. Care and treatment values, preferences, and attitudes of adolescents living with HIV: a review of qualitative literature. 2013. Available at: http://apps.who.int/iris/bitstream/10665/95145/1/WHO_HIV_2013.137_eng.pdf. 2015.
- Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. *PLoS One*. 2009;4(6), e5790.
- Auld AF, Agolory SG, Shiraiishi RW, Wabwire-Mangen F, Kwesigabo G, Mulenga M, et al. Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults—seven African countries, 2004–2013. *Morb Mortal Weekly Rep*. 2014;63(41):1097–103.
- Idele P, Gillespie A, Porth T, Suzuki C, Mahy M, Kasedde S, et al. Epidemiology of HIV and AIDS among adolescents: current status, inequities, and data gaps. *J Acquir Immune Defic Syndr*. 2014;66 Suppl 2: S144–53.
- Ojikutu B, Higgins-Biddle M, Greeson D, Phelps BR, Amzel A, Okechukwu E, et al. The association between quality of HIV care, loss to follow-up and mortality in pediatric and adolescent patients receiving antiretroviral therapy in Nigeria. *PLoS One*. 2014;9(7), e100039.

9. Fish R, Judd A, Jungmann E, O'Leary C, Foster C. Mortality in perinatally HIV-infected young people in England following transition to adult care: an HIV Young Persons Network (HYPNet) audit. *HIV Med.* 2014;15(4):239–44.
10. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. *J Acquir Immune Defic Syndr.* 2009;51(1):65–71.
11. Mellins CA, Tassiopoulos K, Malee K, Moscicki A, Patton D, Smith R, et al. Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. *AIDS Patient Care STDs.* 2011;25(7):413–22.
12. Blum RW, Garell D, Hodgman CH, Jorissen TW, Okinow NA, Orr DP, et al. Transition from child-centered to adult health-care systems for adolescents with chronic conditions: a position paper of the Society for Adolescent Medicine. *J Adolesc Health.* 1993;14(7):570–6.
13. Nehring WM, Betz CL, Lobo ML. Uncharted territory: systematic review of providers' roles, understanding, and views pertaining to health care transition. *J Pediatr Nurs.* 2015;30(5):732–47.
14. Sam-Agudu NA, Bruno T, Ereka S, Ogunson O, Ilozumba J, Badejo O, Busari O, Ezeanolue EE, NISA ACT Study Group, editor. Age at healthcare transitioning for adolescents living with HIV in Nigeria: a national survey. San Francisco: Pediatric Academic Societies Meeting; 2017.
15. Newman C, Persson A, Miller A, Cama E. Bridging worlds, breaking rules: clinician perspectives on transitioning young people with perinatally acquired HIV into adult care in a low prevalence setting. *AIDS Patient Care STDs.* 2014;28(7):381–93.
16. Wiener LS, Kohrt BA, Battles HB, Pao M. The HIV experience: youth identified barriers for transitioning from pediatric to adult care. *J Pediatr Psychol.* 2011;36(2):141–54.
17. Wiener L, Battles H, Ryder C, Zobel M. Transition from a pediatric HIV intramural clinical research program to adolescent and adult community-based care services: assessing transition readiness. *Soc Work Health Care.* 2007;46(1):1–19.
18. Pettitt ED, Greifinger RC, Phelps BR, Bowsky SJ. Improving health services for adolescents living with HIV in sub-Saharan Africa: a multi-country assessment. *Afr J Reprod Health.* 2013;17(4):17–31.
19. Maturio D, Powell A, Major-Wilson H, Sanchez K, De Santis JP, Friedman LB. Development of a protocol for transitioning adolescents with HIV infection to adult care. *J Pediatr Health Care.* 2011;25(1):16–23.
20. Andiman WA. Transition from pediatric to adult healthcare services for young adults with chronic illnesses: the special case of human immunodeficiency virus infection. *J Pediatr.* 2011;159(5):714–9.
21. Vijayan T, Benin AL, Wagner K, Romano S, Andiman WA. We never thought this would happen: transitioning care of adolescents with perinatally acquired HIV infection from pediatrics to internal medicine. *AIDS Care.* 2009;21(10):1222–9.
22. Folayan MO, Cáceres CF, Sam-Agudu NA, et al. *AIDS Behav* 2017;21:2736. <http://doi.org/10.1007/s10461-016-1534-3>.
23. Federal Ministry of Health, Nigeria. National Training Manual on the Health and Development of Adolescent and Young People in Nigeria. 2011. <http://www.health.gov.ng/doc/TrainManualHDAY.pdf>. Accessed 9 Dec 2017.
24. Federal Ministry of Health, Nigeria. Clinical Protocol for the Health and Development of Adolescents and Young People in Nigeria. 2011. <http://www.health.gov.ng/doc/ClinicalProtocol.pdf>. Accessed 9 Dec 2017.
25. Chima CC, Homedes N. Impact of global health governance on country health systems: the case of HIV initiatives in Nigeria. *J Glob Health.* 2015;5(1), 010407.
26. Ezeanolue EE, Powell BJ, Patel D, Olutola A, Obiefune M, Dakum P, et al. Identifying and prioritizing implementation barriers, gaps, and strategies through the Nigeria Implementation Science Alliance: getting to zero in the prevention of mother-to-child transmission of HIV. *J Acquir Immune Defic Syndr.* 2016;72 Suppl 2:S161–6.
27. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. *Med Care.* 2012;50(3):217–26.
28. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. *Am J Public Health.* 1999;89(9):1322–7.
29. Campbell MK, Piaggio G, Elbourne DR, Altman DG, CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. *BMJ.* 2012;345:e5661.
30. Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. p. 2014.
31. Federal Ministry of Health Nigeria, 2016. National Guidelines for HIV Prevention, Treatment and Care. Available at: https://aidsfree.usaid.gov/sites/default/files/ng_national_guidelines_hiv.pdf. Accessed May 2017.
32. Federal Ministry of Health, Nigeria. Guidelines for Young Persons' Participation in Research and Access to Sexual and Reproductive Health Services in Nigeria. 2014. Available at: https://www.popcouncil.org/uploads/pdfs/2014HIV_YoungPersonsSRH-Nigeria.pdf. Accessed May 2017.
33. Federal Ministry of Health, Nigeria. National Guidelines for HIV Prevention, Treatment and Care. 2016. https://www.prepwatch.org/wpcontent/uploads/2017/08/nigeria_national_guidelines_2016.pdf. Accessed 9 Dec 2017.
34. Pharr J, Enejoh V, Mavegam BO, Olutola A, Marick H, Ezeanolue EE. Relationship between Health Locus of Control and Risky Sexual Behaviors among Nigerian Adolescents. *J AIDS Clin Res* 2015;6(6):471. <http://doi.org/10.4172/2155-6113.1000471>.
35. Wallston BS, Wallston KA, Kaplan GD, Maides SA. Development and validation of the Health Locus of Control (HLC) scale. *J Consult Clin Psychol.* 1976;44(4):580.
36. Wallston KA, Wallston BS. Health locus of control scales. Research with the locus of control construct. 1981;1:189–243
37. Corey LMK. "The Mental Health Continuum: From Languishing to Flourishing in Life". *J Health Soc Behav.* 2002;43(2):207–22.
38. Broadhead WE, Gehlbach SH, De Gruy FV, Kaplan BH. The Duke-UNC Functional Social Support Questionnaire: Measurement of social support in family medicine patients. *Med care.* 1988;709–23.
39. Basen-Engquist K, Masse LC, Coyle K, Kirby D, Parcel GS, Banspach S, et al. Validity of scales measuring the psychosocial determinants of HIV/STD-related risk behavior in adolescents. *Health Educ Res.* 1999;14(1):25–38.
40. Keyes C, Wissing M, Potgieter JP, Temane M, Kruger A, van Rooy S. Evaluation of the Mental Health Continuum-short form (MHC-SF) in Setswana-speaking South Africans. *Clin Psychol Psychother.* 2008;15(3):181.
41. Sawicki GS, Lukens-Bull K, Yin X, Demars N, Huang IC, Livingood W, et al. Measuring the transition readiness of youth with special healthcare needs: validation of the TRAQ—Transition Readiness Assessment Questionnaire. *J Pediatr Psychol.* 2011;36(2):160–71.
42. Wood DL, Sawicki GS, Miller MD, Smotherman C, Lukens-Bull K, Livingood WC, et al. The Transition Readiness Assessment Questionnaire (TRAQ): its factor structure, reliability, and validity. *Acad Pediatr.* 2014;14(4):415–22.
43. Zhang LF, Ho JS, Kennedy SE. A systematic review of the psychometric properties of transition readiness assessment tools in adolescents with chronic disease. *BMC Pediatr.* 2014;14(1):4.
44. Hemming K, Girling AJ, Sitch AJ, Marsh J, Lilford RJ. Sample size calculations for cluster randomised controlled trials with a fixed number of clusters. *BMC Med Res Methodol.* 2011;11(1):102.
45. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. *Behav Res Methods.* 2008;40(3):879–91.
46. Positive Connections. Leading information and support groups for adolescents living with HIV. 2017. Available at: <https://www.fhi360.org/resource/positive-connections-leading-information-and-support-groups-adolescents-living-hiv>. 2017.
47. Sam-Agudu NA, Cornelius LJ, Okundaye JN, Adeyemi OA, Isah HO, Wiwa OM, et al. The impact of mentor mother programs on PMTCT service uptake and retention-in-care at primary health care facilities in Nigeria: a prospective cohort study (MoMent Nigeria). *J Acquir Immune Defic Syndr.* 2014;67:S132–8.
48. Africaid Zvandiri. 2017. Available at: <http://www.africaid-zvandiri.org/>. 2017.
49. Baylor International Pediatric AIDS Initiative. Malawi Teen Club Curriculum. 2012. Available at: https://www.k4health.org/sites/default/files/Part_2_Malawi_Teen_Club_Activities_2012_final.pdf. 2017.
50. Chan A, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158:200–7.